Results 221 to 230 of about 3,916,297 (351)

Clinical Outcomes Of Patients Within The Rheumatoid Arthritis Care Pathway Cohort At a Tertiary Care Integrated Delivery Network: A Comparison To Usual Care

open access: yesArthritis Care &Research, Accepted Article.
Objective We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. Methods The care pathway initiative implements guideline‐based best practice alongside multi‐disciplinary team‐based care. Clinical and insurance claims data were extracted to compare
Tarun Sharma   +7 more
wiley   +1 more source

Safety of peripheral intravenous administration of hypertonic saline: a systematic review and meta-analysis. [PDF]

open access: yesFront Med (Lausanne)
Huang SS   +6 more
europepmc   +1 more source

Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis

open access: yesArthritis Care &Research, EarlyView.
Objective Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early ...
Zoe Rutter‐Locher   +8 more
wiley   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

open access: yesArthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava   +48 more
wiley   +1 more source

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

open access: yesArthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech   +4 more
wiley   +1 more source

Peripheral Giant Cell Granuloma: A Case Report and Review of Literature

open access: green, 2013
Shivani Moghe   +3 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy